A study highlights insufficient standardized safety and efficacy assessments for FDA-cleared AI/ML medical devices.
Key Details
- 1Cross-sectional analysis of FDA-cleared AI/ML-enabled devices was conducted.
- 2The study found lack of standardized efficacy and safety reporting in device clearance.
- 3Suggested need for dedicated regulatory pathways and post-market AI/ML safety surveillance.
- 4Study was published in JAMA Health Forum and led by Dr. Ravi B. Parikh.
Why It Matters
As imaging AI tools increasingly enter clinical use, robust regulatory oversight is critical for patient safety and clinician trust. Gaps in FDA reporting and surveillance could impact the safe integration of AI in radiology practice.
Source
EurekAlert
Related News
•EurekAlert
New VIS-Fb Nanobody Probes Transform High-Precision Cellular Imaging
Salk and Einstein researchers have developed visible-spectrum antigen-stabilizable fluorescent nanobodies (VIS-Fbs) for sharper, multi-color live-cell imaging with minimal background noise.
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.